GLYC - グリコ・ミメティックス (GlycoMimetics Inc.) グリコ・ミメティックス



symbol GLYC
会社名 GlycoMimetics Inc (グリコ・ミメティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 GlycoMimetics Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate GMI-1070 (Rivipansel) for the treatment of vaso-occlusive crisis (VOC) a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271 a specific E-selectin inhibitor to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate GMI-1359 that targets both E-selectin and a chemokine receptor CXCR4. The Company is also advancing other preclinical-stage programs which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.   グリコ・ミメティックスは希少薬の発見と開発を行う米国のバイオ医薬品会社。鎌状赤血球病患者の血管閉鎖性発作の治療薬GMI-1070、急性骨髄性白血病と血液凝固障害の治療薬GMI-1271の治験を行う。また、緑膿菌毒性因子をタ―ゲットにした治療薬の開発を行う。   
本社所在地 9708 Medical Center Drive Rockville MD 20850 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-243-1201
設立年月日 37712
市場名 NASDAQ National Market System
ipoyear 2014年
EBITDA EBITDA(百万ドル) -41.46510
終値(lastsale) 13.62
時価総額(marketcap) 586439976.54
時価総額 時価総額(百万ドル) 609.26030
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 379.82560
当期純利益 当期純利益(百万ドル) -39.99956
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 GlycoMimetics Inc revenues was not reported. Net loss increased 42% to $22.8M. Higher net loss reflects researcg and development expense balanc increase of 59% to $17.5M (expense) General_Administrative Expe increase of 26% to $4.3M (expense) Stock-based Compensation in R&D increase of 36% to $853K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.64 to -$0.59.


 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 グリコ・ミメティックス GLYC GlycoMimetics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)